company name https://demo.annual-meeting.in.th/wp-content/uploads/2021/07/Global-COVID-19-Prevention.mp4 Document 1 Document 2 Document 3 Albert Einstein Albert Einstein was a physicist who developed the general theory of relativity. He is considered one of the most…

Mundipharma https://demo.annual-meeting.in.th/wp-content/uploads/2021/07/Doctor-Consulting-With-A-Patient-Sample-Video.mp4

Abstract 503 De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. Nadia Harbeck, Oleg Gluz, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke,…

Abstract 500 Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial. Josephine Lopes Cardozo, Caroline Drukker, Marjanka Schmidt, Laura van ’t Veer, Annuska Glas, Anke Witteveen,…

Abstract LBA1 OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Andrew Tutt,…

Abstract 9001 Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA…

Abstract 9000 First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update…

Abstract 9006 Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. Joshua Bauml, Byoung Chul…

Abstract 8005 IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Heather…

Abstract 6003 Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial. Jun Ma, Yu-Pei Chen, Ying Sun, Qin Zhou, Kun-Yu Yang, Feng…